舒泰神股价跌5.2%，中信保诚基金旗下1只基金重仓，持有35.5万股浮亏损失51.83万元

Group 1 - The core point of the news is that Shutaishen's stock price dropped by 5.2% to 26.60 CNY per share, with a trading volume of 383 million CNY and a turnover rate of 3.13%, resulting in a total market capitalization of 12.709 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under CITIC Prudential has heavily invested in Shutaishen. The CITIC Prudential Zhirui Mixed A Fund (003432) increased its holdings by 60,000 shares in the fourth quarter, bringing the total to 355,000 shares, which accounts for 4% of the fund's net value, making it the sixth-largest holding [2] - The CITIC Prudential Zhirui Mixed A Fund was established on October 21, 2016, with a current size of 134 million CNY. Year-to-date returns are 1.83%, ranking 6888 out of 8861 in its category; the one-year return is 7.03%, ranking 6921 out of 8126; and the return since inception is 72.96% [2] Group 3 - The fund managers of CITIC Prudential Zhirui Mixed A Fund are Wang Rui and Zhu Huiling. Wang Rui has a tenure of 10 years and 276 days, with a total fund asset size of 5.719 billion CNY, achieving a best return of 253.09% and a worst return of -32.84% during his tenure [3] - Zhu Huiling has a tenure of 301 days, managing a total fund asset size of 242 million CNY, with a best return of 7.37% and a worst return of 7.29% during her tenure [3]